Ho Lina, Akada Keith, Messner Hans, Kuruvilla John, Wright Janice, Seki Jack T
, BScPhm, ACPR, is with the Department of Pharmacy, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario.
Can J Hosp Pharm. 2013 Mar;66(2):110-7. doi: 10.4212/cjhp.v66i2.1233.
Patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT), supported by complex drug regimens, are vulnerable to drug therapy problems (DTPs) at interfaces of care after discharge from hospital and may benefit from timely pharmacy interventions and education.
To determine the effect on medication safety of, as well as potential barriers to, incorporating a pharmacist in the multidisciplinary team of an allo-HCT clinic.
Two pharmacists rotated to attend the allo-HCT clinic of a tertiary care, university-affiliated cancer centre between January and June 2010 (coverage for 1 of 3 clinic days per week). For every patient who was seen by a pharmacist, all discharge medications were reconciled from the inpatient ward to the clinic. The pharmacists' primary task was to perform medication reconciliation and to identify and resolve DTPs. The pharmacists also provided medication education to patients and pharmacy consultations to clinic staff. Working with the outpatient pharmacy, the pharmacists helped to clarify prescriptions and drug coverage issues. Medication discrepancies identified and interventions performed by the pharmacists were recorded and were later graded for clinical significance by a panel of clinicians. Patient and staff satisfaction surveys were conducted at random during the study period. Barriers to the flow of patient care and other operational issues were documented.
The 2 pharmacists saw a total of 35 patients over 100 visits. They identified a total of 50 medication discrepancies involving 17 (49%) of the patients and 70 DTPs involving 23 (66%) of the patients. Thirty-one of the 70 DTPs resulted directly from a medication discrepancy. Twenty (95%) of the 21 unintentional medication discrepancies and 7 (70%) of the 10 undocumented intentional medication discrepancies were graded as clinically significant or moderately significant. Satisfaction surveys completed by patients and clinic staff yielded positive responses supporting pharmacists' participation.
Pharmacists working as part of the multidisciplinary team identified and resolved medication discrepancies, thereby improving medication safety at the allo-HCT clinic.
接受异基因造血细胞移植(allo-HCT)的患者,在复杂药物治疗方案的支持下,出院后在医疗护理衔接阶段易出现药物治疗问题(DTPs),可能受益于及时的药学干预和教育。
确定在allo-HCT门诊多学科团队中纳入药剂师对用药安全的影响以及潜在障碍。
2010年1月至6月期间,两名药剂师轮流到一家三级医疗、大学附属癌症中心的allo-HCT门诊坐诊(每周覆盖3个门诊日中的1天)。对于每位由药剂师诊治的患者,对从住院病房到门诊的所有出院用药进行核对。药剂师的主要任务是进行用药核对,识别并解决药物治疗问题。药剂师还为患者提供用药教育,并为门诊工作人员提供药学咨询。药剂师与门诊药房合作,帮助澄清处方和药物覆盖范围问题。记录药剂师识别出的用药差异和实施的干预措施,随后由一组临床医生对其临床意义进行分级。在研究期间随机进行患者和工作人员满意度调查。记录患者护理流程的障碍和其他操作问题。
两名药剂师在100多次就诊中共诊治了35名患者。他们共识别出50处用药差异,涉及17名(49%)患者,以及70个药物治疗问题,涉及23名(66%)患者。70个药物治疗问题中有31个直接由用药差异导致。21处无意用药差异中的20处(95%)和10处未记录的有意用药差异中的7处(70%)被评为具有临床意义或中度临床意义。患者和门诊工作人员完成的满意度调查给出了支持药剂师参与的积极反馈。
作为多学科团队一员工作的药剂师识别并解决了用药差异,从而提高了allo-HCT门诊的用药安全性。